1. Home
  2. GOTU vs LYEL Comparison

GOTU vs LYEL Comparison

Compare GOTU & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GOTU

Gaotu Techedu Inc.

HOLD

Current Price

$1.69

Market Cap

345.8M

Sector

Real Estate

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$11.85

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOTU
LYEL
Founded
2014
2018
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
345.8M
320.1M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
GOTU
LYEL
Price
$1.69
$11.85
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
717.2K
132.9K
Earning Date
05-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$17.33
N/A
Revenue Next Year
$13.02
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.40
$8.49
52 Week High
$4.12
$45.00

Technical Indicators

Market Signals
Indicator
GOTU
LYEL
Relative Strength Index (RSI) 49.80 30.53
Support Level $1.65 N/A
Resistance Level $2.01 $13.88
Average True Range (ATR) 0.10 1.25
MACD 0.02 0.07
Stochastic Oscillator 58.95 4.56

Price Performance

Historical Comparison
GOTU
LYEL

About GOTU Gaotu Techedu Inc.

Gaotu Techedu Inc is a technology-driven education company that provides online live courses in a large-class setting backed by its proprietary technology infrastructure. The company offers courses in large-class format, which amplifies the benefits of online education and allows it to rapidly expand its student base. It operates solely in the PRC and all assets are located in the PRC. The learning services that the company offers include Traditional Learning Services, Non-Academic Tutoring Services, and College Student and Adult Education Services. It derives maximum revenue from Learning Services and also from Educational content & digitalized learning products.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: